Regulatory issues set up pitfalls in the race to Rituxan biosimilars
October 30, 2012 | Analyst Insight
Electronics giant Samsung halted clinical trials for its SAIT101, a biosimilar for Roche's blockbuster Rituxan. Though it did not offer any further explanation, a source close to the company cites...
About Lux Research
Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.